Oxicodona/Naloxona Viatris shortage — ES supply status & alternatives

Oxicodona/Naloxona Viatris

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES🌐 CO

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Oxicodona/Naloxona Viatris
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 5 resolved events

◷

1–46 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🌐

INVIMA · 21h ago

Medium

🇪🇸

Spain

AEMPS · 1mo ago

Medium

Verified timeline regulator events

🇪🇸 28 Apr 2026

medium reported

🇪🇸 20 Nov 2025

Shortage resolved

🇪🇸 30 Sept 2025

Shortage resolved

🌐 22 July 2025

medium reported

🇪🇸 23 Apr 2025

Shortage resolved

🇪🇸 15 Oct 2024

Shortage resolved

Sources official regulators

🌐

INVIMA

verified 21h ago

verify ↗

🇪🇸

AEMPS

verified 8d ago

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.